Kenes Group, like many others, has had to find solutions for delegates who could not travel from early on into the Covid-19 crisis. As vital decisions had to be made at a moment’s notice, Kenes Group managed to keep cancellations to a minimum and postpone many of the planned events.
Adapting to the new situation, the Group organised an entirely virtual event, the 2nd AAT-AD/PD™ Focus Meeting 2020 at the beginning of April. The Meeting presented all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
Its success led Kenes Group to create its latest white paper which explores the expedition into the virtual conference. Download the white paper here.